Drugs / NEZUTATUG
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05919537 | Sep 2023 → Mar 2031 expected | malignant pancreatic neoplasm, metastatic neoplasm, non-small cell lung carcinoma | Hummingbird Bioscience | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05910827 | Feb 2024 → Dec 2027 expected | cervical squamous cell carcinoma, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, nasopharyngeal carcinoma +2 | Hummingbird Bioscience | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05057013 | Nov 2021 → Nov 2025 overdue | castration-resistant prostate carcinoma, cervical cancer, colorectal cancer, endometrial cancer +10 | Cancer Research UK | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NEZUTATUG | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315023 ↗ |
| Known as | HMBD-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05057013 ↗ |
| Modality | Monoclonal antibody | “HMBD-001 is a type of drug called a monoclonal antibody.” NCT05057013 ↗ |
| Route | Intravenous | “administered once a week as a 120-minute intravenous (IV) infusion.” NCT05057013 ↗ |